Literature DB >> 27732727

Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study.

Petter Gjersvik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27732727     DOI： 10.1001/jamadermatol.2016.2427

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  3 in total

1.  Aging and the treatment of basal cell carcinoma.

Authors:  Shreya Sreekantaswamy; Justin Endo; Amy Chen; Daniel Butler; Lily Morrison; Eleni Linos
Journal:  Clin Dermatol       Date:  2019-06-16       Impact factor: 3.541

Review 2.  Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.

Authors:  Zoe Apalla; Chrysoula Papageorgiou; Aimilios Lallas; Elena Sotiriou; Elizabeth Lazaridou; Efstratios Vakirlis; Athanassios Kyrgidis; Demetrios Ioannides
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-05-10

Review 3.  Updates on the Management of Non-Melanoma Skin Cancer (NMSC).

Authors:  Artur Fahradyan; Anna C Howell; Erik M Wolfswinkel; Michaela Tsuha; Parthiv Sheth; Alex K Wong
Journal:  Healthcare (Basel)       Date:  2017-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.